Ruxolitinib
JAK/STAT pathway inhibitor; Inhibits JAK1 and JAK2
Overview
CANCER RESEARCH
· Suppresses erythroid progenitor colony formation from peripheral blood mononuclear cells of polycythemia vera patients with the constitutively active JAK2 V617F mutation. Reduces malignant cell proliferation and decreases interleukin-6 and TNF-α signaling in a JAK2 V617F-driven mouse model of myeloproliferative disorder (Quintás-Cardama et al.).
OTHER
· Promotes hair regrowth in a mouse model of alopecia areata (Xing et al.).
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Resources and Publications
Educational Materials (2)
Publications (3)
Abstract
Abstract
Abstract
Legal Statement:
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.